The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-fluoro-7-methyl-N-((1R,3S)-3-((S)-3-(N-methylmethylsulfonamido)pyrrolidin-1-yl)cyclohexyl)-1H-indole-2-carboxamide ID: ALA5091591
PubChem CID: 156599545
Max Phase: Preclinical
Molecular Formula: C22H31FN4O3S
Molecular Weight: 450.58
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Cc1ccc(F)c2cc(C(=O)N[C@@H]3CCC[C@H](N4CC[C@H](N(C)S(C)(=O)=O)C4)C3)[nH]c12
Standard InChI: InChI=1S/C22H31FN4O3S/c1-14-7-8-19(23)18-12-20(25-21(14)18)22(28)24-15-5-4-6-16(11-15)27-10-9-17(13-27)26(2)31(3,29)30/h7-8,12,15-17,25H,4-6,9-11,13H2,1-3H3,(H,24,28)/t15-,16+,17+/m1/s1
Standard InChI Key: ZLVKIBLQXFILMA-IKGGRYGDSA-N
Molfile:
RDKit 2D
31 34 0 0 0 0 0 0 0 0999 V2000
4.4494 0.9394 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4.0392 1.6551 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
3.6245 0.9420 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-4.7937 -0.8854 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.7949 -1.7166 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0768 -2.1313 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0786 -0.4708 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.3600 -0.8817 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.3551 -1.7119 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5641 -1.9639 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.0800 -1.2894 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5719 -0.6207 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-4.0812 0.3578 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2512 -1.2845 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.8327 -1.9997 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.8411 -0.5643 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.0150 -0.5532 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.0758 -2.9600 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
0.3981 -1.2721 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2232 -1.2693 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6373 -0.5509 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2200 0.1661 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3886 0.1648 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6275 0.8877 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.4475 0.9787 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6122 1.7909 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8905 2.1985 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2800 1.6381 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3660 2.1351 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.4449 2.9600 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7949 1.9985 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
4 5 2 0
5 6 1 0
6 9 2 0
8 7 2 0
7 4 1 0
8 9 1 0
9 10 1 0
10 11 2 0
11 12 1 0
12 8 1 0
7 13 1 0
11 14 1 0
14 15 2 0
14 16 1 0
17 16 1 1
6 18 1 0
17 19 1 0
17 23 1 0
19 20 1 0
20 21 1 0
21 22 1 0
22 23 1 0
22 24 1 1
24 25 1 0
25 26 1 0
26 27 1 0
27 28 1 0
28 24 1 0
26 29 1 6
29 2 1 0
29 30 1 0
2 31 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 450.58Molecular Weight (Monoisotopic): 450.2101AlogP: 2.62#Rotatable Bonds: 5Polar Surface Area: 85.51Molecular Species: BASEHBA: 4HBD: 2#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 8.51CX LogP: 1.46CX LogD: 0.32Aromatic Rings: 2Heavy Atoms: 31QED Weighted: 0.73Np Likeness Score: -1.42
References 1. Lampe JW, Alford JS, Boriak-Sjodin PA, Brach D, Cosmopoulos K, Duncan KW, Eckley ST, Foley MA, Harvey DM, Motwani V, Munchhof MJ, Raimondi A, Riera TV, Tang C, Thomenius MJ, Totman J, Farrow NA.. (2021) Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies., 12 (10.0): [PMID:34671445 ] [10.1021/acsmedchemlett.1c00272 ] 2. Alford JS, Lampe JW, Brach D, Chesworth R, Cosmopoulos K, Duncan KW, Eckley ST, Kutok JL, Raimondi A, Riera TV, Shook B, Tang C, Totman J, Farrow NA.. (2022) Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies., 13 (7.0): [PMID:35859865 ] [10.1021/acsmedchemlett.2c00167 ]